Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 315

1.

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, Scriba TJ, Akite EJ, Ayles HM, Bollaerts A, Demoitié MA, Diacon A, Evans TG, Gillard P, Hellström E, Innes JC, Lempicki M, Malahleha M, Martinson N, Mesia Vela D, Muyoyeta M, Nduba V, Pascal TG, Tameris M, Thienemann F, Wilkinson RJ, Roman F.

N Engl J Med. 2019 Oct 29. doi: 10.1056/NEJMoa1909953. [Epub ahead of print]

PMID:
31661198
2.

Gastrointestinal Cancers: Fine-Tuning the Management of Rectal, Esophageal, and Pancreas Cancers.

Olsen JR, Apisarnthanarax S, Murphy JD, Tait D, Huguet F, Hallemeier CL, Jabbour SK.

Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):1-10. doi: 10.1016/j.ijrobp.2019.04.037. Review. No abstract available.

PMID:
31422802
3.

Are methane emissions from mangrove stems a cryptic carbon loss pathway? Insights from a catastrophic forest mortality.

Jeffrey LC, Reithmaier G, Sippo JZ, Johnston SG, Tait DR, Harada Y, Maher DT.

New Phytol. 2019 Oct;224(1):146-154. doi: 10.1111/nph.15995. Epub 2019 Jul 20.

PMID:
31211874
4.

Exacerbation of the credit assignment problem in rats with lesions of the medial prefrontal cortex is revealed by Bayesian analysis of behavior in the pre-solution period of learning.

Wang J, Tait DS, Brown VJ, Bowman EM.

Behav Brain Res. 2019 Oct 17;372:112037. doi: 10.1016/j.bbr.2019.112037. Epub 2019 Jun 13.

PMID:
31202862
5.

Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.

Sclafani F, Wilson SH, Cunningham D, Gonzalez De Castro D, Kalaitzaki E, Begum R, Wotherspoon A, Capdevila J, Glimelius B, Roselló S, Thomas J, Tait D, Brown G, Oates J, Chau I.

Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32507. [Epub ahead of print]

PMID:
31199501
6.

iAMES: An inexpensive, Automated Methane Ebullition Sensor.

Maher DT, Drexl M, Tait DR, Johnston SG, Jeffrey LC.

Environ Sci Technol. 2019 Jun 4;53(11):6420-6426. doi: 10.1021/acs.est.9b01881. Epub 2019 May 23.

PMID:
31117543
7.

Gastrointestinal Cancers: Management of Rectal, Hepatocellular, Pancreatic, and Esophageal Cancers.

Hallemeier CL, Olsen JR, Murphy JD, Tait D, Apisarnthanarax S, Huguet F, Jabbour SK.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):1-9. doi: 10.1016/j.ijrobp.2018.12.052. No abstract available.

PMID:
30967220
8.

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.

Norris EJ, Zhang Q, Jones WD, DeStephanis D, Sutker AP, Livasy CA, Ganapathi RN, Tait DL, Ganapathi MK.

J Pathol. 2019 Jul;248(3):352-362. doi: 10.1002/path.5264. Epub 2019 May 14.

9.

More rapid reversal learning following overtraining in the rat is evidence that behavioural and cognitive flexibility are dissociable.

Dhawan SS, Tait DS, Brown VJ.

Behav Brain Res. 2019 May 2;363:45-52. doi: 10.1016/j.bbr.2019.01.055. Epub 2019 Jan 30.

PMID:
30710612
10.

Author's Reply.

Brown J, Drury L, Crane EK, Anderson WE, Tait DL, Higgins RV, Naumann RW.

J Minim Invasive Gynecol. 2019 Mar - Apr;26(3):574. doi: 10.1016/j.jmig.2018.11.017. Epub 2018 Nov 30. No abstract available.

PMID:
30508654
11.

Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.

Naumann RW, Morris JC, Tait DL, Higgins RV, Crane EK, Drury LK, Amacker-North L, Templin M, Brown J.

Gynecol Oncol. 2018 Dec;151(3):477-480. doi: 10.1016/j.ygyno.2018.10.003. Epub 2018 Oct 8.

PMID:
30309722
12.

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitié MA, Tameris M, Malahleha M, Innes JC, Hellström E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR.

N Engl J Med. 2018 Oct 25;379(17):1621-1634. doi: 10.1056/NEJMoa1803484. Epub 2018 Sep 25.

13.

Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.

Athauda A, Watkins D, Mohammed K, Chau I, Starling N, Rao S, Tait D, Aitken K, Cunningham D.

Anticancer Res. 2018 Oct;38(10):5943-5949. doi: 10.21873/anticanres.12940.

PMID:
30275223
14.

When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.

Brown J, Drury L, Crane EK, Anderson WE, Tait DL, Higgins RV, Naumann RW.

J Minim Invasive Gynecol. 2019 Jul - Aug;26(5):902-909. doi: 10.1016/j.jmig.2018.09.765. Epub 2018 Sep 18.

PMID:
30240899
15.

Neoadjuvant rectal score: run with the hare and hunt with the hounds.

Sclafani F, Kalaitzaki E, Cunningham D, Tait D, Brown G, Chau I.

Ann Oncol. 2018 Nov 1;29(11):2261-2262. doi: 10.1093/annonc/mdy403. No abstract available.

16.

Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.

Suliman S, Luabeya AKK, Geldenhuys H, Tameris M, Hoff ST, Shi Z, Tait D, Kromann I, Ruhwald M, Rutkowski KT, Shepherd B, Hokey D, Ginsberg AM, Hanekom WA, Andersen P, Scriba TJ, Hatherill M; H56-035 Trial Group.

Am J Respir Crit Care Med. 2019 Jan 15;199(2):220-231. doi: 10.1164/rccm.201802-0366OC.

PMID:
30092143
17.

Is organ preservation in rectal cancer ready for prime time?

Tekkis P, Tait D, Cunningham D, Brown G.

Lancet. 2018 Jun 23;391(10139):2480-2482. doi: 10.1016/S0140-6736(18)31324-2. No abstract available.

PMID:
29976455
18.

Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.

Norris EJ, Jones WD, Surleac MD, Petrescu AJ, Destephanis D, Zhang Q, Hamadeh I, Kneisl JS, Livasy CA, Ganapathi RN, Tait DL, Ganapathi MK.

Gynecol Oncol Rep. 2018 Jan 17;23:41-44. doi: 10.1016/j.gore.2018.01.005. eCollection 2018 Feb.

19.

Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?

Bhoday J, Glimelius B, Tait D, Glynne-Jones R, Adams R, Brown G.

Colorectal Dis. 2018 May;20 Suppl 1:97-99. doi: 10.1111/codi.14088. Review.

PMID:
29878687
20.

Session 4: Shaping radiotherapy for rectal cancer: should this be personalized?

Dattani M, Marijnen C, Moran B, Tait D, Cunningham C, Rodriguez-Bigas M, Brown G.

Colorectal Dis. 2018 May;20 Suppl 1:92-96. doi: 10.1111/codi.14087. Review.

PMID:
29878670

Supplemental Content

Support Center